PHIA Koninklijke Philips N.V.

Philips introduces next generation of Advanced Visualization Workspace – IntelliSpace Portal 12 – with AI capabilities at RSNA 2020

Philips introduces next generation of Advanced Visualization Workspace – IntelliSpace Portal 12 – with AI capabilities at RSNA 2020

November 30, 2020

  • Next generation of Philips’ advanced radiology visualization platform leverages image post-processing and artificial intelligence (AI) to deliver quantitative clinical insights, drive increased diagnostic confidence, simplify workflows, and reduce time-to-report
  • New features include AI algorithms for lung nodule detection, cardiac functional analysis, and quantification of pulmonary infiltrates associated with COVID-19 patients
  • Intelligent, automated and connected multi-modality, multi-vendor suite of applications supports follow-up and communication across clinical care pathways

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the next generation of Philips Advanced Visualization Workspace – IntelliSpace Portal 12 for radiologists. Launched at this year’s virtual Radiological Society of North America Scientific Assembly and Annual Meeting (), IntelliSpace Portal features a robust set of new AI-assisted quantitative assessment and automatic results generation features to support the diagnostic workflow, including follow-up and communication across cardiology, pulmonology, oncology and neurology. Its AI-assisted pulmonary capabilities include the assessment of complex lung conditions associated with COVID-19.

“In the COVID era, the automatic detection and characterization of pulmonary infiltrates, especially in viral pneumonia, is very important,” said Hans-Ulrich Kauczor, professor and chairman of radiology at the University of Heidelberg in Germany. “IntelliSpace Portal’s AI-assisted quantitative assessment capabilities allow general radiologists and residents on call to get the necessary support to help identify COVID pneumonia, which is differentiated from other diagnoses. This also plays a significant role for longitudinal analysis and follow-up.“

“The immediate and complex long-term needs of COVID-19 patients, combined with the growth of elective care, has highlighted the continued need for advanced fully-integrated radiology solutions that support efficient diagnosis, follow-up and communication across multiple clinical domains,” said Calum Cunningham, General Manager of Enterprise Diagnostic Informatics at Philips. “The new generation of IntelliSpace Portal adds numerous AI-enabled features that automatically generate quantitative measurements, simplify workflows, and make radiology data available anywhere it’s clinically relevant in an organization.”

Expanding its ecosystem for radiology solutions, new clinical software packages [1] in cardiology, pulmonology, oncology and neurology being launched with IntelliSpace Portal 12, several of which have been integrated in collaboration with Pie Medical Imaging BV or Riverain Technologies, include:

Cardiology

MR Cardiac Analysis – Pre-processing images to deliver AI-based right ventricle and left ventricle segmentation to ensure accurate volumetric and functional measurements, enabling completion of a full cardiac MRI functional analysis in less than 5 minutes [2].

MR Caas™ 4D Flow Analysis – To reduce analysis time and improve reliability of valvular flow quantification [3], Caas [4] MR 4D Flow visualizes and quantifies blood flow patterns in a patient’s heart and main arteries.

Pulmonology

CT Pulmo Auto Results [5] – Featuring AI algorithms trained on complex pulmonary CT scans, including those of COVID-19 patients, CT Pulmo Auto Results software performs automatic lung segmentation and lesion segmentation, together with classification of ground glass opacities/consolidation. Its automatically generated reports include volume summaries and lesion distribution data to help in the quantitative assessment of pulmonary infiltrates, enhancing diagnostic confidence without increasing reading time.

Oncology

CT ClearRead™ CAD Lung Nodule Analysis [6] – featuring AI-based detection and characterization for various nodule types including solid, part-solid and ground-glass lung nodules, enabling to perform nodule searches 26% faster and detect 29% of previously missed nodules [7].

Neurology

CT Brain Perfusion Analysis – IntelliSpace Portal 12 now supports automatic brain perfusion measurements instantly available on PACS with the option of automatically emailing perfusion results to a stroke patient’s clinicians within two minutes to reduce door-to-needle time.

Additional Enhancements

The software also includes a new photorealistic volume rendering [8] technology using an interactive virtual light source to improve the visualization of volumes in terms of their depth and relationship to other key anatomies – enhancing its use as an educational and communication tool.

Other enhancements in IntelliSpace Portal include workflow innovations for vascular analysis to deliver faster results, new automatic lesion segmentation propagation between time-points for longitudinal tumor tracking, new CaasTM [4] myocardial strain quantification software, and enhanced automatic capabilities for CT coronaries analysis.

Philips Radiology Workflow Suite at RSNA 2020

At RSNA 2020, Philips will showcase an integrated suite of offerings for the first time, introducing key solutions that come together to enhance the entire radiology workflow to address the most pressing operational challenges across diagnostic and interventional radiology. Philips Advanced Visualization Workspace – IntelliSpace Portal – is a key component for Image and data interpretation within Philips Radiology Workflow Suite, connecting patient data across departments to create interoperability for greater clinical intelligence and analysis, supported by AI-tools such as an algorithm for the detection of COVID-19 lesions. Visit for more information on Philips integrated workflow solutions to connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.

Philips’ triple duty of care

The COVID-19 pandemic continues to highlight how interconnected the world’s social, economic and environmental challenges are. Philips remains fully focused on delivering against its triple duty of care: meeting critical customer needs, safeguarding the health and safety of its employees, and ensuring business continuity. As a purpose-driven health technology company, Philips is applying its innovation strength to improve the health and well-being of people. The company is deeply committed to doing business responsibly and sustainably, a range of challenging new environmental, social and governance targets.

[1] Some IntelliSpace Portal functionalities may not be available in all territories.

[2] Average RV/LV analysis time measured on validation study 4.2 min +/- 0.4

[3] V.P. Kamphuis et al., Automated Cardiac Valve Tracking for Flow Quantification with Four-dimensional Flow MRI, Radiology, 2019 Jan;290(1):70-78

[4] Caas is a trademark of Pie Medical Imaging BV.

[5] The functionality may not be available in all territories. In the United States of America, the CT Pulmo Auto Results can only be used during the National Emergency Concerning the Novel Coronavirus Disease (COVID-19). The CT Pulmo Auto Results functionality is exempt from premarket notification according to the FDA Guidance document for Imaging Systems During the Coronavirus Disease 2019 (COVID-19), and was therefore not cleared by the FDA. It is offered via a trial license only for the duration of the national emergency, until further notice.

[6] ClearRead CT is a trademark of Riverain Technologies.

[7] ShihChung et al. AJR 2018; 210:480-488

[8] IntelliSpace Portal’s Photorealistic Volume Rendering is not intended for diagnostic image review

For further information, please contact:

Kathy O’Reilly

Philips Global Press Office

Tel.:

E-mail :

Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
30/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adyen: Preview 2H25. Aperam: In-line 4Q25, upbeat medium-term outlook balances short-term consensus risk. Ayvens: Fast Car (UCS normalisation). Barco: 4Q25 preview, mixed performance. Lotus Bakeries: Another beat on every line. Orange Belgium: 2H25 EBITDAal beat on lower sales, much better 2026 guidance. Philips: CMD & 4Q25 preview, execution is key. RELX: FY25 preview. Universal Music Group: Peer Warner Music 4% revenue and 11% OIBDA beat

Livio Luyten ... (+4)
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste
Michiel Declercq
  • Michiel Declercq

Philips Ready to Start from a Clean Sheet

Running up to the CMD on 10 February, we initiate coverage on Philips with an Accumulate rating and a €27.5 TP. While we see potential for the company to positively surprise with its 2028 margin ambitions, investors will likely focus on the phasing, as 2026 margins will still be held back by tariff normalization. Nevertheless, with the majority of Respironics-related uncertainty now behind us, we believe Philips has room to increase shareholder returns and potentially announce a new share buybac...

 PRESS RELEASE

Philips named a Clarivate Top 100 Global Innovator for the 13th consec...

Philips named a Clarivate Top 100 Global Innovator for the 13th consecutive year January 21, 2026 Highest-ranking medical technology company recognized in the Clarivate Top 100 Global Innovators list for 2026Innovations for healthcare professionals and consumers that support better care delivery and improve people’s health and well-beingIndustry-leading commitment to R&D, with over EUR 1.7 billion invested annually, equivalent to approximately 9% of sales Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been named a for the 13th consecutive ...

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch